Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Microtubules in Signaling01:22

Microtubules in Signaling

1.7K
The primary cilium, made up of microtubules, acts as antennae on the cell surfaces for relaying external stimuli into the cells. These fine hair-like structures are present, generally one per cell. These are non-motile cilia in a 9+0 microtubules arrangement, where the central pair of microtubules are absent. The primary cilia arise from the basal body embedded in the cell membrane. Intraflagellar transport (IFT) carries requisite proteins from the cytoplasm to the cilium because the primary...
1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.7K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
Assembly of Complex Microtubule Structures01:32

Assembly of Complex Microtubule Structures

1.9K
Complex microtubule structures are present in resting cells and in dividing cells. In resting cells, they are responsible for maintaining the cellular architecture, tracks for intracellular transport, positioning of organelles, assembly of cilia and flagella. They mediate the bipolar spindle assembly for chromosomal segregation and positioning of the cell division plate in dividing cells. The formation of microtubule complex structures depends on the cell type, cell stage, and cell function.
1.9K
Microtubule Associated Proteins (MAPs)01:42

Microtubule Associated Proteins (MAPs)

4.4K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
4.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fatal Pericarditis and Cardiac Tamponade During Selumetinib Treatment for Pericardial Neurofibroma.

The Journal of dermatology·2026
Same author

Focal dermal hypoplasia with clinical features mimicking classic hypohidrotic ectodermal dysplasia and cardiofaciocutaneous syndrome.

European journal of dermatology : EJD·2025
Same author

Genotype-phenotype correlation for skin and neuropsychiatric features in tuberous sclerosis complex.

The British journal of dermatology·2025
Same author

Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis.

eLife·2024
Same author

Diagnostic flow analysis of tuberous sclerosis complex in Japan: a retrospective claims database study.

Orphanet journal of rare diseases·2024
Same author

Calvarial Thickening in Tuberous Sclerosis Complex.

World neurosurgery·2024

Related Experiment Video

Updated: Jul 20, 2025

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin
08:07

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin

Published on: March 24, 2023

1.9K

Tuberous Sclerosis Complex.

Mari Wataya-Kaneda1,2

  • 1Department of Neurocutaneous Medicine, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.

The Keio Journal of Medicine
|August 2, 2023
PubMed
Summary

Tuberous Sclerosis Complex (TSC) is an inherited disorder causing tumors due to mTORC1 overactivation. New mTORC1 inhibitors offer effective treatment but require careful management and research into topical formulations for skin lesions.

Keywords:
diagnostic criteriamTORC1ministry of health labor and welfaretopical formulation of mTORC1 inhibitortuberous sclerosis complex

More Related Videos

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles
07:54

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles

Published on: November 5, 2020

5.2K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.2K

Related Experiment Videos

Last Updated: Jul 20, 2025

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin
08:07

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin

Published on: March 24, 2023

1.9K
Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles
07:54

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles

Published on: November 5, 2020

5.2K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.2K

Area of Science:

  • Genetics and Molecular Biology
  • Neurology
  • Dermatology

Background:

  • Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder characterized by systemic hamartomas and TSC-Associated Neuropsychiatric Disorders (TAND).
  • Disease pathogenesis is linked to constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway, resulting from mutations in TSC1 or TSC2 genes.
  • Advances in diagnostics and understanding of TSC pathogenesis have significantly impacted its diagnosis and treatment.

Purpose of the Study:

  • To summarize the current understanding of TSC pathogenesis and treatment strategies.
  • To highlight the emergence of mTORC1 inhibitors as a therapeutic approach for TSC.
  • To discuss the development of a collaborative care model and topical treatments for TSC.

Main Methods:

  • Review of existing literature on TSC pathogenesis, diagnosis, and treatment.
  • Analysis of the impact of mTORC1 inhibitors on TSC symptoms.
  • Examination of the development of the "TSC Board" and topical mTORC1 inhibitor formulations.

Main Results:

  • mTORC1 inhibitors are effective against TSC symptoms but can cause systemic side effects.
  • A "TSC Board" model has been established to facilitate cross-disciplinary care.
  • Topical mTORC1 inhibitor formulations have been developed to manage TSC-related skin lesions and reduce systemic side effects.

Conclusions:

  • The management of TSC has evolved from purely symptomatic treatment to targeted therapies like mTORC1 inhibitors.
  • A multidisciplinary approach and specialized care models are crucial for managing TSC effectively.
  • Ongoing research, including the development of topical treatments, aims to improve patient outcomes and minimize treatment-related side effects.